The firm's Genomics revenues increased 89 percent, while Data and Services revenues rose 43 percent year over year.

Gain insights into Personalis, Inc.'s Q1 2025 performance, including a 52% test volume increase, 39% revenue growth, and progress in Medicare ...

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care ...

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care ...